Tu J - Search Results

Year	Number of Results
1962	1
1963	4
1964	2
1965	4
1967	1
1969	2
1970	5
1971	3
1972	2
1973	4
1974	1
1975	2
1976	3
1977	1
1978	2
1979	3
1980	3
1981	3
1982	3
1983	3
1984	4
1985	4
1986	3
1987	4
1988	5
1989	3
1990	5
1991	4
1992	10
1993	8
1994	6
1995	10
1996	13
1997	13
1998	18
1999	11
2000	18
2001	29
2002	19
2003	47
2004	33
2005	48
2006	53
2007	66
2008	68
2009	72
2010	80
2011	90
2012	105
2013	122
2014	142
2015	153
2016	189
2017	237
2018	286
2019	297
2020	308
2021	357
2022	390
2023	378
2024	409
2025	421
2026	1

1

Prevalence and patterns of multimorbidity in China during 2002-2022: A systematic review and meta-analysis.

Hu Y, Wang Z, He H, Pan L, Tu J, Shan G. Hu Y, et al. Among authors: tu j. Ageing Res Rev. 2024 Jan;93:102165. doi: 10.1016/j.arr.2023.102165. Epub 2023 Dec 12. Ageing Res Rev. 2024. PMID: 38096988 Free article.

2

Glutamine metabolism in breast cancer and possible therapeutic targets.

Li S, Zeng H, Fan J, Wang F, Xu C, Li Y, Tu J, Nephew KP, Long X. Li S, et al. Among authors: tu j. Biochem Pharmacol. 2023 Apr;210:115464. doi: 10.1016/j.bcp.2023.115464. Epub 2023 Feb 26. Biochem Pharmacol. 2023. PMID: 36849062 Review.

3

Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope.

Zhang X, Tang B, Luo J, Yang Y, Weng Q, Fang S, Zhao Z, Tu J, Chen M, Ji J. Zhang X, et al. Among authors: tu j. Mol Cancer. 2024 Nov 15;23(1):255. doi: 10.1186/s12943-024-02130-8. Mol Cancer. 2024. PMID: 39543600 Free PMC article. Review.

4

Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy.

Tang B, Zhu J, Shi Y, Wang Y, Zhang X, Chen B, Fang S, Yang Y, Zheng L, Qiu R, Weng Q, Xu M, Zhao Z, Tu J, Chen M, Ji J. Tang B, et al. Among authors: tu j. Mol Cancer. 2024 Jul 5;23(1):137. doi: 10.1186/s12943-024-02049-0. Mol Cancer. 2024. PMID: 38970074 Free PMC article.

5

Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.

Yan C, Yue Y, Guan Y, Bu B, Ke Q, Duan R, Deng H, Xue Q, Jiang H, Xiao F, Yang H, Chang T, Zou Z, Li H, Tan S, Xiao H, Zhou H, Zhang H, Meng Q, Li W, Li W, Guo J, Zhang Y, Li Z, Tu J, Shi J, Li W, Lee M, Chen Y, Tao X, Zhao S, Li P, Zhao C; Batoclimab Study Team. Yan C, et al. Among authors: tu j. JAMA Neurol. 2024 Mar 4;81(4):336-45. doi: 10.1001/jamaneurol.2024.0044. Online ahead of print. JAMA Neurol. 2024. PMID: 38436998 Free PMC article.

6

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.

Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, Sethi G, Zhao P, Liu S. Zhang M, et al. Among authors: tu j. Mol Cancer. 2025 May 7;24(1):136. doi: 10.1186/s12943-025-02305-x. Mol Cancer. 2025. PMID: 40336045 Free PMC article. Review.

7

Epigenetic Regulatory Axis MIR22-TET3-MTRNR2L2 Represses Fibroblast-Like Synoviocyte-Mediated Inflammation in Rheumatoid Arthritis.

Fang Y, Huang W, Zhu X, Wang X, Wu X, Wang H, Hong W, Yan S, Zhang L, Deng Y, Wei W, Tu J, Zhu C. Fang Y, et al. Among authors: tu j. Arthritis Rheumatol. 2024 Jun;76(6):845-856. doi: 10.1002/art.42795. Epub 2024 Mar 7. Arthritis Rheumatol. 2024. PMID: 38221658

8

ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I.

Li C, Wang B, Tu J, Liu C, Wang Y, Chen J, Huang Y, Liu B, Yuan X. Li C, et al. Among authors: tu j. Cell Death Dis. 2024 Jul 20;15(7):519. doi: 10.1038/s41419-024-06911-3. Cell Death Dis. 2024. PMID: 39033176 Free PMC article.

9

OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.

Li WF, Chiang MF, Weng HC, Yang JJ, Wu HS, Wu SY, Chen YJ, Lu CH, Tu JS, Hsu RY, Shia CS, Huang TY, Lai MT. Li WF, et al. Among authors: tu js. Mol Cancer Ther. 2025 Feb 4;24(2):163-175. doi: 10.1158/1535-7163.MCT-24-0588. Mol Cancer Ther. 2025. PMID: 39786401 Free PMC article.

10

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. Le X, et al. Among authors: tu j. J Clin Oncol. 2025 Feb;43(4):403-411. doi: 10.1200/JCO.24.00533. Epub 2024 Oct 8. J Clin Oncol. 2025. PMID: 39378386 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,118 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,118 results

Results by year